First Light Asset Management LLC Buys 203,373 Shares of Vaxcyte, Inc. $PCVX

First Light Asset Management LLC grew its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 143.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 345,157 shares of the company’s stock after purchasing an additional 203,373 shares during the quarter. Vaxcyte makes up approximately 1.2% of First Light Asset Management LLC’s portfolio, making the stock its 25th largest holding. First Light Asset Management LLC owned 0.23% of Vaxcyte worth $20,064,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of PCVX. Smartleaf Asset Management LLC grew its stake in Vaxcyte by 156.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after buying an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in Vaxcyte by 1,463.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after acquiring an additional 600 shares during the last quarter. IFP Advisors Inc lifted its position in Vaxcyte by 72.8% during the 2nd quarter. IFP Advisors Inc now owns 560 shares of the company’s stock worth $33,000 after acquiring an additional 236 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after acquiring an additional 184 shares during the period. Finally, CIBC Private Wealth Group LLC boosted its holdings in Vaxcyte by 22,500.0% during the third quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after acquiring an additional 1,350 shares during the period. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Wall Street Zen upgraded Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Zacks Research raised Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Vaxcyte has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

Insider Transactions at Vaxcyte

In other Vaxcyte news, insider Harpreet S. Dhaliwal sold 17,000 shares of Vaxcyte stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $55.00, for a total transaction of $935,000.00. Following the sale, the insider owned 76,756 shares in the company, valued at $4,221,580. The trade was a 18.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the business’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $53.00, for a total transaction of $530,000.00. Following the completion of the sale, the chief financial officer directly owned 104,395 shares in the company, valued at $5,532,935. This trade represents a 8.74% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 124,588 shares of company stock valued at $6,835,592. Company insiders own 3.30% of the company’s stock.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $59.51 on Thursday. The company has a market cap of $8.86 billion, a PE ratio of -7.80 and a beta of 1.22. The firm has a fifty day moving average price of $58.41 and a two-hundred day moving average price of $56.32. Vaxcyte, Inc. has a fifty-two week low of $30.81 and a fifty-two week high of $65.00.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. During the same quarter last year, the business posted ($1.22) EPS. Analysts expect that Vaxcyte, Inc. will post -7.6 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.